RxDoctor Payments Data

Amelia Underwood, PA

Physician Assistant · Hollister, CANPI 1083065395

Payments from drug & device makers

$6,316in general payments, 2019–2025

Across 268 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$678
  • Johnson & Johnson$543
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$507
  • Lilly USA, LLC$442
  • Takeda Pharmaceuticals U.S.A., Inc.$293
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,27299%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,316 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$95,577
Medicare patients
328
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$73,201
JardianceEmpagliflozin12$20,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,838
EliquisApixaban13$13,425
Albuterol Sulfate HfaAlbuterol Sulfate59$2,580
Atorvastatin Calcium163$1,868
Lisinopril92$703
Gabapentin63$677
Omeprazole44$653
Levothyroxine Sodium42$598
Ezetimibe26$578
Tamsulosin Hcl35$574
Amlodipine Besylate86$569
Metformin Hcl60$565
Escitalopram Oxalate30$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$507$73,20122 claims
Boehringer IngelheimJardiance$239$20,30312 claims
GSKTrelegy Ellipta$98$18,83818 claims
PfizerEliquis$67$13,42513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Hollister

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →